Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Event Reporting
        • Educational Events
        • Non-Price Benefit Reports
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
        • 2020
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2021
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / Latest news / News 2021 / Patients and economy to benefit from ‘medicine manufacturing’ roadmap

Patients and economy to benefit from ‘medicine manufacturing’ roadmap

March 2, 2021 By Admin

2 March 2021

Canberra, ACT

Australia’s peak body for affordable medicines, today welcomed the Government’s launch of its Medicine-Medical Product Manufacturing Road Map, describing it as an exciting opportunity to build Australia’s capability as an advanced manufacturer and exporter of high quality and safe medicines.

The independent Chair of the Generic and Biosimilar Medicines Association (GBMA), Ms Jane Halton AO, today applauded the initiative which is part of the Government’s $1.3 billion Modern Manufacturing Initiative (MMI), announced before the last budget.

GBMA, and its members, have been working closely with the Government, and other key stakeholders, to protect patients against any disruption to the international medicine supply chains, especially at the height of the COVID-19 pandemic last year.

“Now, as we navigate through this destructive global pandemic, the Government has recognised that the medicines sector can, and should be, a priority enabler of our long term economic recovery,” Ms Halton said.

The Government’s road map outlines ‘investing in highly efficient and automated facilities could offer Australia some opportunities to manufacture certain generics and biosimilars.’

Board member and founding Chair of the largest Australian-owned pharmaceutical company Arrotex, Mr Dennis Bastas, was a key member of the Minister for Industry’s medicine manufacturing taskforce.

“We know medicine manufacturing has long been a sector slowly disappearing from our shores but with the advanced technology, innovation, the right policy levers, funding and industry will; we can see a vibrant and burgeoning home-grown, export-driven pharmaceutical sector develop again,” Mr Bastas said.

GBMA CEO, Ms Marnie Peterson, welcomed the innovative collaboration that the roadmap inspired.

“This roadmap recognises that Australia needs to build its own sovereign medicine manufacturing capability whilst ensuring patients can still access a reliable and resilient global supply chain of medicines,” Ms Peterson said.

We look forward to working closely with the Government in ensuring both outcomes can be achieved to the benefit of our economy and our citizens.”

For more information about the Government’s medicine manufacturing roadmap, please follow this link.

-ENDS-

ABOUT GBMA

The Generic and Biosimilar Medicines Association (GBMA) is the peak representative body of generic and biosimilar medicine suppliers in Australia.

Its members ensure that all Australians are offered high quality generic and biosimilar medicines, whilst providing affordable community health outcomes that benefit all Australians.

For more information, please contact the GBMA – admin@gbma.com.au or visit www.gbma.com.au

ENQUIRIES

Jannette Cotterell
Executive Counsel Australia
0419 204 059
jcotterell@executivecounsel.com.au

Filed Under: News 2021

Our Members

Juno
Juno
Sandoz logo
Sandoz logo
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
generic_partners
generic_partners
southern_cross
southern_cross
commercial_eyes
commercial_eyes
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

Active Ingredient Prescribing – a game changer for patients: Prescription reforms to further support patient safety

February 1, 2021

1 February 2021 Canberra, ACT Canberra: Australia’s patients will be the big winners out of a new law that will prioritise … More...

Announcement of Independent Chair

December 9, 2020

9 December 2020 Canberra, ACT Global health policy powerhouse, Jane Halton … More...

Confidence in biosimilar medicines, amongst specialists, GP’s and Pharmacists

December 8, 2020

12 November 2020 Canberra, ACT New research shows prescriber … More…

© 2021 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us